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Epilepsy is a common neurological condition with significant resource implications. An estimation was performed in France
of the direct medical cost of patients presented with newly diagnosed seizures and followed during the first two years after
diagnosis. This estimation was based on the service utilization data collected from French prospective cohort study (CAROLE:
1942 patients enrolled). Costs were estimated in a societal perspective in 1998 value. The impact on the costs of different
factors like age, aetiologic categorization and severity of seizures (type and number of seizures), and treatment by anti-epileptic
drugs (AEDs) was analysed. The mean annual direct epilepsy-related costs per patient were estimated to be 14 305 F and 3766 F
for the first and the second year of follow-up respectively, 68% and 40% of the costs were devoted to inpatient care. Costs during
the first year were highly sensitive to aetiologic categorization of seizures at inclusion and to other clinical parameters. Second-
year costs had a much lower variance and were sensitive to frequency of seizures and the fact of being treated or not by AEDs.
Our data emphasize the importance of seizure control as means of reducing the costs of epilepsy especially during the first year
of follow-up.
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INTRODUCTION
Epilepsy is an important public health problem be-
cause of its burden on individuals and society in
terms of morbidity, direct and indirect costs. Epileptic
seizures are common events. According to epidemio-
logical surveys performed in industrialized countries,
the prevalence of epilepsy is estimated to be approx-
imately 5–8 per 1000 with an incidence of approx-
imately 50–100 per 100 000 per year1. The medical
and social care of this disorder entails large costs re-
lated to hospitalization, diagnostic procedures, drugs
and social assistance2, 3. It is generally accepted that
the direct medical costs of diagnosed epilepsy are very
dependent on the time period considered after diag-
nosis4, 5. The first year integrates all costs related to
diagnosis for all incident epileptic cases, whereas in
the subsequent years a large proportion of patients will
never experience any relapse, thus reducing the mean
costs. Large differences then depend on the prognostic
groups of patients5.
The cost of epilepsy has been rarely estimated on
the basis of direct observations of real medical con-
sumption on large samples of patients because of the
scarcity of large population studies in this area4, 6, 7.
It was then an interesting opportunity to derive such
cost estimates from a cohort study of epileptic pa-
tients followed for 2 years after initial diagnosis. This
French cohort study named CAROLE (Active Coor-
dination of the Longitudinal Observational Network
in Epilepsy) was characterized by a large sample size
and the collection of very detailed clinical parameters
on the enrolled patients that allowed an analysis of the
main possible factors of variation. However, the vari-
ables available to describe non-medical direct costs
and indirect costs were considered inadequate to per-
mit any reliable estimation despite the fact that indi-
rect costs represent a major part of the societal bur-
den of epilepsy2, 5, 8. Neither was any quality-of-life
questionnaire collected9, 10. Therefore, the results pre-
sented here are restricted to direct medical costs.
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MATERIALS AND METHOD
Study population
The CAROLE study is a prospective, observational,
and naturalistic survey of patients with newly di-
agnosed unprovoked seizures, enrolled by volunteer
specialists in neurology and neuropediatry through-
out France. Participating specialists (N = 243) were
asked to enroll all consecutive different patients seen
in their current public and/or liberal practice from
1 May, 1995 until 30 June, 1996. One thousand nine
hundred forty two patients could be enrolled and fol-
lowed up for 2 years. The cohort included men and
women aged more than 1 month, presenting with a
newly diagnosed unprovoked seizure. The only exclu-
sion criteria concerned the patients’ inability to partic-
ipate in a long-term follow-up for social reasons.
Data collection
Data was collected and recorded on standard case re-
port forms at inclusion (baseline) and at each patient’s
follow-up visit for a minimum of 2 years. Being de-
signed as a purely observational and naturalistic sur-
vey, the follow-up was to interfere as little as possible
with the patient’s usual care. In particular, no attempt
has been made in the present analysis of the data to
perform a critical review of diagnosis and care11. Con-
sequently, no specific visit or procedure was planned
in the study protocol and hence we considered that
there were no protocol-induced costs. In case of no
visit occurring on a 6-month period, investigators were
only asked to have an informal contact with the patient
(or his GP) to collect minimal information about his
current clinical status. All documents were checked in
real time by the medical monitor. Anonymity of pa-
tients was strictly maintained.
At inclusion, data collected addressed the descrip-
tion of the first diagnosed seizure (index seizure) in
terms of circumstances, duration and type, and pos-
sible history of other seizures. General characteristics
on health, clinical examination, procedures, drug ther-
apy, other use of medical services, hospitalizations,
and socioeconomic status of the patients (or their rela-
tives for the younger patients), diagnostic conclusions
and therapeutic decisions were also recorded. At each
follow-up visit, physicians were asked to collect in-
formation about the recurrent seizure(s), use of medi-
cal services, and modification of socioeconomic status
since the last contact. They also had to record results
of recent diagnostic procedures, to re-evaluate their di-
agnosis, and to describe current treatments (drug com-
pliance, side effects, etc.).
Direct costs estimation
The general approach used here is a so-called
‘incidence-based’ cost analysis restricted to a 2-year
follow-up period after diagnosis5. This approach is
based on a longitudinal analysis of individuals tak-
ing into account the temporal aspects of epilepsy. This
method is an alternative to cross-sectional approaches
based on observation of samples of patients present in
a population at all stages of evolution of the disease.
Direct medical costs included all epilepsy-related
items of medical consumption, i.e. physicians’ vis-
its, hospitalizations, diagnostic investigations, labora-
tory tests, and antiepileptic drugs. Non-medical costs
(transportation costs, residential care and unpaid care
or services provided by patients relatives) were not
documented in our study.
Costs were estimated for each patient, using the
items provided in the case report forms in combina-
tion with unit cost determined from external sources.
No database belonging to National Sickness Funds or
other third-party payers was used to estimate individ-
ual costs. A societal perspective was chosen, meaning
that all costs either reimbursed by the public Sickness
Funds and/or private insurance or patient’s out-of-
pocket expenses were included. Costs of drugs were
calculated on the basis of the current prices used in
France. They are restricted to outpatient consumption.
It may be noticed that in France all drugs prescribed
for outpatient care have a regulatory national price re-
sulting from an agreement with Health Authorities.
These prices are listed in the VIDAL 98. Costs are
then calculated by using these unit prices, dose and
duration of prescriptions.
All items of medical consumption used for in-
patient care were valued globally by multiplying a
daily cost per category of ward by the corresponding
length of stay.
Main unit costs used and their sources are sum-
marized in Table 1. Concerning outpatient care, unit
costs are based on reimbursement rates currently in
use in France. All costs have been converted to French
Francs 1998 based on evolution rates of health expen-
ditures. Finally, direct medical costs were calculated
as the sum of all costs described here above for each
patient on a per annum basis (i.e. year 1 and year 2
after diagnosis).
Statistical methods
Patients were shared according to age group (less
than 16 years, 16–60 years and over 60 years), ae-
tiologic categorization at inclusion (idiopathic, cryp-
togenic, symptomatic) and seizure severity after 1-
year follow-up (mean number of seizures per month).
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Table 1: Main unit costs and sources of data (1FF = 0.15 = 0.17US$).
Type of costs Unit cost Source
(FF 1998)
Inpatient care: Analytical Accounting from ‘Assistance
Emergency room 2701 Publique Hoˆpitaux de Paris’ taken as
Neurology ward 3061 reference prices.
Outpatient care:
GPs visits 115
Neurologist and other visits 150 ‘Nomenclature Ge´ne´rale des Actes
Usual EEG 411 Professionnels’
CT scan (contrast media not included) 900
MRI (contrast media not included) 2300
Table 2: Socio-demographic characteristics of the cohort.
Age group
1 month–15 years > 15–60 years >60 years
Gender, females (%) 49 44 47
Age, mean (SD) 7 (4) 31 (12) 70 (7)
Working, of the active population (%) — 76.2 —
Number of patients (%)
With 1-year follow-up 717 (40.8) 870 (49.5) 169 (9.7)
With 2-year follow-up 633 (43.2) 696 (47.6) 135 (9.2)
Cumulative length of follow-up 1350 1566 304
(patient years)
Since cost variables were not normally distributed, we
used the non-parametric test for global cost differ-
ences across patient categories (Kruskall–Wallis) and,
in case of significance, Mann–Whitney tests were used
for category-by-category comparisons. Finally, a mul-
tivariate model of analysis of variance was used in
order to quantify the individual contribution of each
clinical factor according to a descending hierarchical
approach. This method allows analysis of the relation-
ships between the annual direct costs considered as a
quantitative variable and a series of clinical and demo-
graphic explanatory variables described in categories
(2 or 3 modalities). The analysis was performed in us-
ing the PROC/GLM from SASr12.
RESULTS
The CAROLE cohort
The main characteristics of the cohort are presented
in Table 2 to allow comparison with other avail-
able epidemiological data4, 5. The cumulative length
of follow-up was 3220 patient years. Of 1942 pa-
tients initially enrolled, 1756 (90.4%) and 1464 pa-
tients (75.4%) respectively had a 1- and 2-year follow-
up with a fully documented medical consumption. The
mean values presented below were calculated for the
first year on patients with at least a fully documented
1-year follow-up period. The same principle was ap-
plied for the second year. The younger age group
(1 month to 15 years) represented 40.8% of the co-
hort and the older group (over 60 years) 9.7%. The
percentage of the adult population at work was 76.2%.
Health care management
Table 3 presents the rates of utilization for different
services, procedures and treatment related to epileptic
seizures. The bottom line takes into account at least
one of the whole set of medical items. For the first
year, the result is of course 100% due to the design
of the study, but decreases to 87–90% on the second
year, meaning that 10–13% of patients had no medical
consumption in relation with epilepsy in the second
year of follow-up. Concerning inpatient care, the per-
centage applies to any hospital stay, whatever its du-
ration, including day hospitalizations. Concerning the
utilization rates of diagnostic procedures, the figures
presented in Table 3 apply only to those performed in
out-patient care. The perspective was here to estimate
costs and not to fully describe the medical manage-
ment of these patients. This aspect will be described in
an upcoming publication. The percentage of patients
in each age group treated by at least one AED was cal-
culated whatever the duration of treatment during the
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year considered. No minimum duration was used as a
threshold.
Annual direct medical cost of epilepsy
The results on annual direct costs of patients with
newly diagnosed seizures are presented in two steps
in order to avoid any misinterpretation of the data. In
Table 4, the mean annual costs per patient in each age
group having used the corresponding item of medical
care are displayed. For example, the mean cost of in-
patient care is 11 335FF (1FF = 0.15 = 0.17US$)
during the first year of follow-up for a patient 16–60 of
age, who has been hospitalized. Table 3 shows that the
corresponding mean length of stay was 5 days and that
only 66% of patients were concerned. Table 5 supplies
the corresponding costs calculated on the whole popu-
lation in each age group, whether hospitalized or not.
This last value is used for global estimates of mean
costs.
The results suggest that direct medical costs for
these patients are depending on the age group. But,
these differences are only statistically significant for
the first year of follow-up (P = 0.0001) and this is
true only for the older age group (over 60 years) as
compared with the two others. The most significant
contributor to the total cost was inpatient care regard-
less of age. It accounted for 68% in the first year of
follow-up and for 40%, i.e. at a same proportion as
AEDs, in the second year.
Direct costs according to clinical factors
The preceding results were disaggregated according to
the main clinical parameters available in the CAROLE
study. These clinical criteria were defined as follow-
ing:
• ‘Etiologic categorization’: of patients at inclusion
according to the ILAE recommendations (idio-
pathic, cryptogenic and symptomatic)13;
• ‘Seizures pattern’: this item concerned the seizures
experienced by the patient at the time of diagno-
sis (index seizure) or the history of seizures having
occurred previously, if any. Three categories were
used:
‘single’: this category concerns the patients pre-
senting with only a single seizure at the time of
diagnosis (one seizure at the time of inclusion);
‘multiple’: this category concerns the patients with
an history of undiagnosed seizure(s) before diag-
nosis whatever the time elapsed until the index
seizure;
‘inaugural status epilepticus’: in this last category,
we included also the cases of inaugural multiple
seizures (cluster of seizures) having occurred in a
single 24-h interval.
• ‘Seizure frequency at 1 year’14. It was estimated as
a monthly mean calculated over a 6-month period
about 1 year after diagnosis. The distribution of
this frequency is very skewed and we chose to put
a cut-off value at 30 in the analysis among those
presenting with an active epilepsy.
• ‘Treatment by AEDs’. It was considered for each
year of follow-up separately and used here as a di-
chotomous variable. As mentioned earlier, no min-
imum treatment duration was used to categorize a
patient as being treated.
The results presented in Table 6 are ranked for each
parameter in ascending order in terms of mean costs
for the first year of follow-up. In each variable, the
global differences in costs per category appeared sta-
tistically significant (P < 0.0001). However, the dif-
ferences in costs for the second year were not signif-
icant in two cases: when comparing cryptogenic vs.
idiopathic seizures, and ‘multiple’ seizures vs. ‘inau-
gural status epilepticus’. It may be noticed that the ini-
tial characteristics of seizures (aside from the etiologic
class) do not modify significantly the second year of
follow-up costs.
The interpretation of these last results was, however,
made difficult due to the existing correlations among
all parameters. For this reason, a multivariate model of
variance was used, the results of which are presented
in Table 7.
A reference subgroup of patients was defined as
presenting with the less-severe condition among the
largest age group. It was comprised of adults, with a
single cryptogenic seizure at diagnosis followed by no
recurrent seizure at 1-year follow-up and who were
never treated by AEDs. The mean annual cost in this
subgroup for the first year of follow-up was found to
be 7664F (value of the intercept coefficient).
The model provides parameter estimates that may be
interpreted as the extra cost contributions to this base-
line value associated with the category considered, all
other parameters being controlled. The P-values in
the second column of Table 7 indicate the statistical
significance of each variable in the model (difference
from zero).
The results are presented in Table 7. In summary,
being in one among the following categories respec-
tively, brings an extra cost in the order of magnitude
of 4000–5000FF: either being younger or older (un-
der 15 or over 60 years of age), or having an active
epilepsy (with a number of seizures at 1 year of less
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Table 3: Drugs and medical service utilization rates (to nearest 1%) by age group and by year.
Age Group
1 month–15 years >15–60 years >60 years
(% of patients) (% of patients) (% of patients)
Year 1
Inpatient care 63 (6,3a) 66 (5,0a) 73 (10,7a)
Outpatient care
Neurologist visits 97 (3,6b) 97 (3,5b) 94 (3,1b)
Other physician visits 86 (6,4b) 83 (6,1b) 86 (7,6b)
EEG, at least 1 91 81 64
CT scan or MRI, at least 1 39 57 44
Laboratory tests 53 51 53
AEDs 81 81 86
Other investigations 3 2 5
At least one medical item 100% 100% 100%
Year 2
Inpatient care 12 (7,7a) 6 (5,2a) 7 (8,8a)
Outpatient care
Neurologist visits 77 (1,6b) 63 (1,4b) 56 (1,8b)
Other physician visits 25 (2,4b) 26 (3,1b) 26 (7,8b)
EEG, at least 1 59 39 28
CT scan or MRI, at least 1 3 3 2
Laboratory tests 28 23 33
AEDs 81 82 85
Other investigations 1 0 0
At least one medical item 90 87 88
a Average annual length (number of days) of hospitalization by inpatient.
b Average number of visits by patient using this medical service.
than 30 per month) or being treated by AEDs. Con-
versely, a patient presenting with idiopathic seizures
decreases the baseline cost by 5310F. On the other
hand, a patient presenting with symptomatic seizures
or suffering more than 30 seizures per month at 1 year,
contributed much more to the baseline cost (9045F and
28 936F, respectively). The first-year period costs ap-
peared highly sensitive to all clinical parameters con-
sidered, but with different contributions. These could
be sorted in descending order: (1) aetiologic catego-
rization at inclusion (idiopathic, cryptogenic, symp-
tomatic); (2) number of seizures at 1 year; (3) age
group (15–60, under 15, over 60 years); (4) pattern of
seizure (‘single’, ‘multiple’, ‘inaugural status epilepti-
cus’); (5) being treated or not by AEDs.
Conversely, the second-year costs had a much lower
variance and were only sensitive to two characteris-
tics of the patients: the disease severity (number of
seizures) at one year and the fact of being treated or
not by AEDs.
DISCUSSION
The mean annual direct medical epilepsy-related costs
per patient were estimated 14 305F and 3766F for the
first and the second year of follow-up, respectively,
with inpatient care services accounting for 68% and
40% of the total mean annual direct costs (see Table 5).
This estimation was based on the service utilization
data collected in a cohort study in which 1942 patients
were enrolled. Costs were estimated in a societal per-
spective in 1998 value.
It is difficult to compare these results with similar
published values due to the differences in perspective
and methodology among studies. Concerning French
data, we have not found any comparable results in the
literature.
Another study which provided direct costs for the
period after diagnosis was performed in the UK and
based on the NGPSE4. Our results were much higher:
£611 (about 6110FF) vs. 14 305FF for the mean di-
rect costs for the first year of follow-up, that is more
than two times higher. The ratio between the costs of
the first and the subsequent years are, however, sim-
ilar (36.2% vs. 30% in our study) and also the share
of costs devoted to AEDs out of the total direct costs
(12% and 8% for the CAROLE study in the first year).
It would be interesting to know if this difference was
due to discrepancies in terms of unit costs or medical
resource consumption. It was difficult to fully answer
this question in absence of detailed unit cost data and
direct observations on real utilization rates in the UK
study. It is probable that both aspects play a role. It is
unclear whether the UK study included all diagnostic
procedures performed at the moment of enrolment as
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Table 4: Mean cost/user of each item by age group and by year (1FF = 0.15 = 0.17US$).
Type of costs Age group Total
1 month–15 years >15–60 years >60 years
Year 1 (mean)
Inpatient care 17 689FF 11 335FF 21 003FF 14 870FF
Outpatient care
Neurologist visits 544FF 501FF 462FF 515FF
Other visits 292FF 302FF 380FF 306FF
EEG 1 634FF 1 053FF 868FF 1 298FF
CT scan or MRI 2 847FF 2 821FF 2 576FF 2 808FF
Laboratory tests 492FF 484FF 495FF 488FF
AEDs 1 159FF 1 596FF 1 506FF 1 410FF
Other investigations 383FF 400FF 504FF 410FF
Total Direct Costs 15 643FF 12 212FF 19 404FF 14 305FF
Year 2 (mean)
Inpatient care 20 246FF 10 658FF 19 965FF 17 179FF
Outpatient care
Neurologist visits 268FF 238FF 271FF 255FF
Other visits 392FF 363FF 972FF 432FF
EEG 776FF 523FF 546FF 663FF
CT scan or MRI 2 679FF 2 906FF 2 363FF 2 767FF
Laboratory tests 315FF 301FF 338FF 312FF
AEDs 1 615FF 2 064FF 1 699FF 1 837FF
Other investigations 163FF 199FF — 168FF
Total Direct Costs 5 286FF 3 375FF 3 953FF 4 270FF
Table 5: Mean direct costs per patient included in the cohort by age group and by year (in FF 1998) (1FF = 0.15 = 0.17US$).
Type of costs Age group Total %
1 month–15 years >15–60 years >60 years
Year 1 (mean)
Inpatient care 11 102FF 7 479FF 15 410FF 9 722FF 68
Outpatient care
Neurologist visits 530FF 484FF 434FF 498FF 3
Other physician visits 252FF 252FF 328FF 259FF 2
EEG 1 436FF 837FF 509FF 1 050FF 7
CT scan or MRI 1 112FF 1 605FF 1 143FF 1 359FF 10
Laboratory tests 261FF 248FF 263FF 255FF 2
AEDs 939FF 1 297FF 1 292FF 1 150FF 8
Other investigations 11FF 10FF 24FF 11FF 0
Total Direct Costs 15 643FF 12 212FF 19 404FF 14 305FF 100
Year 2 (mean)
Inpatient care 2 527FF 628FF 1 331FF 1 514FF 40
Outpatient care
Neurologist visits 206FF 151FF 150FF 175FF 5
Other physician visits 97FF 94FF 252FF 110FF 3
EEG 433FF 192FF 142FF 292FF 8
CT scan or MRI 89FF 92FF 53FF 87FF 2
Laboratory tests 88FF 70FF 110FF 81FF 2
AEDs 1 312FF 1 696FF 1 447FF 1 507FF 40
Other investigations 2FF 0FF 0FF 1FF 0
Total Direct Costs 4 751FF 2 924FF 3 484FF 3 766FF 100
the French study did. The hospitalization rate was thus
11% in UK as compared with 65% in France with an
average length of stay of 4.5 and 6 days respectively.
But most hospitalizations in France were caused in the
first year by the index seizure(s) care and associated
work-up. The referrals to neurologists are also proba-
bly very different between the two countries due to the
large differences in the number of these specialists.
Another explanation may be related to the distribu-
tion by age of our population of newly diagnosed pa-
tients. As compared with other epidemiological data
in the literature4, 5 it appears that the CAROLE sam-
ple is probably under-represented in the over 60 years
age group. The proportion of these patients was around
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Table 6: Mean annual direct costs of epilepsy per patient in the cohort according to different clinical categories (in FF 1998)
(1FF = 0.15 = 0.17US$).
Year 1 Year 2
Etiologic categorization at inclusiona
Idiopathic 9 036FF 2 580FF
Cryptogenic 13 539FF 3 775FF
Symptomatic 25 676FF 5 797FF
Pattern of seizure(s) at inclusiona
‘Single’ 12 946FF 2 563FF
‘Multiple’b 14 213FF 4 609FF
‘Inaugural status epilepticus’b 20 783FF 3 665FF
Seizure frequency at 1 yeara
None 12 555FF 2 455FF
1–29 per month 17 196FF 4 653FF
>30 per month 47 099FF 37 588FF
Treated by AEDsa
No 9 410FF 636FF
Yes 15 408FF 4 451FF
Total 14 305FF 3 766FF
a P < 0.0001 except ‘idiopathic vs. cryptogenic’ and ‘multiple vs. inaugural status epilepticus’ for the second year (non significant
difference).
b See definition in the text.
Table 7: Model of analysis of variance of direct medical cost during the first year of follow-up (1FF = 0.15 = 0.17US$).
Variable P Modalities Reference Parameter P
group estimates (FF)
Age 0.0019 1 month–15 years 3 547 0.0026
>15–60 years x 0 —
>60 years 4 715 0.0126
Aetiologic category 0.0001 Idiopathic −5 310 0.0001
Cryptogenic x 0 —
Symptomatic 9 045 0.0001
Pattern of seizures at inclusion 0.0066 Not status epilepticusa x 0 —
Status epilepticusa 5 142 0.0066
Number of seizures per month at 1 year 0.0001 No seizure x 0 —
1–30 per month 3 690 0.0049
≥30 per month 28 936 0.0001
Treated by AED 0.0112 Yes 3 529 0.0112
No x 0 —
Intercept 7 664 0.0001
a Inaugural (see definition in the text).
10% here while it represented 24% in UK4 and 33%
in the US5. However, correcting for this potential bias
will yield an increase in the mean costs in France.
CONCLUSIONS
Our data emphasize the importance of seizure control
as a means of reducing the costs of epilepsy, especially
during the first year of follow-up.
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